The company designed this system to use with the company’s previously approved Cervista human papillomavirus (HPV) HR test.
The HPV HR test uses the company’s proprietary Invader technology to detect 14 types of HPV that are associated with cervical cancer and precancerous lesions.
The Cervista HTA system automates the DNA extraction and detection steps of the HPV HR test facilitating users to walk away after loading the instrument and return the next morning to review the test results.
Hologic president and CEO Rob Cascella said the Cervista HTA system automates their Cervista HPV HR test, providing higher throughput, improved chain of custody and accurate results.
